Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor

BJU International

Volumn 99, Issue 3, 2007, Pages 680-686

  Nishiguchi, Jun ^a,b   Kwon, Dong Deuk ^a,c   Kaiho, Yasuhiro ^a   Chancellor, Michael B ^a   Kumon, Hiromi ^b   Snyder, Peter B ^d   Yoshimura, Naoki ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b OKAYAMA UNIVERSITY   (Japan)

^c Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Bladder outlet obstruction; Detrusor overactivity; Non voiding contractions; PDE4; Rat; Type 4 phosphodiesterase

Indexed keywords

CYCLIC AMP; IC 486051; PHOSPHODIESTERASE IV INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CONTRACTION; BLADDER NECK STENOSIS; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CYSTOMETRY; DETRUSOR MUSCLE; DOSE RESPONSE; FEMALE; MICTURITION; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; RAT; RESIDUAL VOLUME; SMOOTH MUSCLE RELAXATION; URETHRA; URINE VOLUME;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; FEMALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER NECK OBSTRUCTION; URINARY BLADDER, OVERACTIVE;

EID: 33846917518     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06643.x     Document Type: Article

References (28)

1. Thomas AW, Abrams P. Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder. BJU Int 2000; 85 (Suppl. 3): 57-68
2. Leach GE, Trockman B, Wong A, Hamilton J, Haab F, Zimmern PE. Post-prostatectomy incontinence: urodynamic findings and treatment outcomes. J Urol 1996; 155: 1256-9
3. O'Connor LT Jr, Vaughan ED Jr, Felsen D. In vivo cystometric evaluation of progressive bladder outlet obstruction in rats. J Urol 1997; 158: 631-5
4. Francis SH, Turko IV, Corbin JD. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 2001; 65: 1-52
5. Eardley I. The role of phosphodiesterase inhibitors in impotence. Expert Opin Investig Drugs 1997; 6: 1803-10
6. Polson JB, Strada SJ. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1996; 36: 403-27
7. Torphy TJ, Undem BJ, Cieslinski LB, Luttmann MA, Reeves ML, Hay DW. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J Pharmacol Exp Ther 1993; 265: 1213-23
8. Truss MC, Uckert S, Stief CG, Forssmann WG, Jonas U. Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effects of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res 1996; 24: 129-34
9. Truss MC, Uckert S, Stief CG et al. Effects of various phosphodiesterase-inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro. Neurourol Urodyn 1996; 15: 59-70
10. Longhurst PA, Briscoe JA, Rosenberg DJ, Leggett RE. The role of cyclic nucleotides in guinea-pig bladder contractility. Br J Pharmacol 1997; 121: 1665-72
11. Qiu Y, Kraft P, Craig EC, Liu X, Haynes-Johnson D. Identification and functional study of phosphodiesterases in rat urinary bladder. Urol Res 2001; 29: 388-92
12. Qiu Y, Kraft P, Craig EC, Liu X, Haynes-Johnson D. Cyclic nucleotide phosphodiesterases in rabbit detrusor smooth muscle. Urology 2002; 59: 145-9
13. Bonoczk P, Gulyas B, Adam-Vizi V et al. Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull 2000; 53: 245-54
14. Gillespie JI. Phosphodiesterase-linked inhibition of nonmicturition activity in the isolated bladder. BJU Int 2004; 93: 1325-32
15. Snyder P, Loughney K, Florio VA. Relaxation of bladder strips by inhibition of cyclic nucleotide phosphodiesterase type 4 (PDE4). J Urol 2005; 173: 43A
16. Tanaka H, Kakizaki H, Shibata T, Mitsui T, Koyanagi T. Effect of preemptive treatment of capsaicin or resiniferatoxin on the development of pre-micturition contractions after partial urethral obstruction in the rat. J Urol 2003; 170: 1022-6
17. Herzer WA, Thomas NJ, Carcillo JA, Tofovic SP, Jackson EK. Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines. J Cardiovasc Pharmacol 1998; 32: 769-76
18. Chuang YC, Fraser MO, Yu Y et al. Analysis of the afferent limb of the vesicovascular reflex using the neurotoxin, resiniferatoxin and capsaicin. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1302-10
19. Bevan S, Storey N. Modulation of sodium channels in primary afferent neurons. Novartis Found Symp 2002; 241: 144-58
20. Andersson KE. Changes in bladder tone during filling: pharmacological aspects. Scand J Urol Nephrol Suppl 1999; 201: 67-72
21. Uckert S, Stief CG, Lietz B, Burmester M, Jonas U, Machtens SA. Possible role of bioactive peptides in the regulation of human detrusor smooth muscle - functional effects in vitro and immunohistochemical presence. World J Urol 2002; 20: 244-9
22. Drake MJ, Harvey IJ, Gillespie JI. Autonomous activity in the isolated guinea pig bladder. Exp Physiol 2003; 88: 19-30
23. Gillespie JI, Harvey IJ, Drake MJ. Agonist- and nerve-induced phasic activity in the isolated whole bladder of the guinea pig: evidence for two types of bladder activity. Exp Physiol 2003; 88: 343-57
24. Gillespie JI. The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int 2004; 93: 478-83
25. Gillespie JI. Noradrenaline inhibits autonomous activity in the isolated guinea pig bladder. BJU Int 2004; 93: 401-9
26. Lagou M, Gillespie JI, Andersson KE, Kirkwood T, Drake MJ. Bladder volume alters cholinergic responses of the isolated whole mouse bladder. J Urol 2006; 175: 771-6
27. Brading AF, McCloskey KD. Mechanisms of Disease: specialized interstitial cells of the urinary tract - an assessment of current knowledge. Nat Clin Pract Urol 2005; 2: 546-54
28. Giembycz MA. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005; 5: 238-44